Could a Weight-Loss drug slow endometrial cancer growth?

NCT ID NCT07065552

First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 30 times

Summary

This study tests whether tirzepatide, a drug used for weight loss and diabetes, can slow tumor growth in obese patients with endometrial cancer. About 20 participants will take the drug before their scheduled hysterectomy. Researchers will compare tumor samples taken before and after treatment to see if the drug reduces cancer cell activity.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lineberger Comprehensive Cancer Center

    RECRUITING

    Chapel Hill, North Carolina, 27599, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.